Please assess the completion status of the following clinical trial:

Trial Title: TDM of Generic Lopinavir/Ritonavir 200/50 mg

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Evidence of HIV infection (confirmed positive ELISA and/or documented history of measurable HIV RNA)~3. Age\> 18 years~4. On a standard PI containing HAART regimen with 2 NRTIs with a VL \< 50 copies for at least 12 weeks OR ARV-naive patients, or patient on a NNRTI based regimen~5. Currently having no AIDS defining illness~6. Willing to adhere to the protocol requirements~Exclusion Criteria:~1. Any history of taking CYP450 inhibitors or inducers, or any gastric acid-reducing drugs within 14 days of enrollment in the study~2. Current pregnancy or lactating~3. Active opportunistic infection~4. ALT/ AST more than 2 x upper limit~5. creatinine more than 1.5 time the upper limit~6. Relevant history or current condition, illness that might interfere with drug absorption, distribution, metabolism or excretion~7. History of sensitivity/idiosyncrasy to the drug or chemically related compounds or excipients which may be employed in the study.~8. Active drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).